ABSI vs JNJ

Absci's score has been significantly downgraded due to material deterioration in its financial performance and a major clinical setback. The Q4 2025 earnings miss was substantial, with full-year 2025 revenue declining 38% YoY, signaling a clear operational stumble. Furthermore, the explicit halting of the ABS-101 program due to disappointing Phase 1 data is a critical blow to its internal pipeline...

Johnson & Johnson (JNJ) remains a fundamentally strong, diversified healthcare conglomerate with an impressive market capitalization. While possessing robust financials, wide economic moats, and consistent performance, its sheer size ($579.46B) fundamentally misaligns with the criteria for 10x growth within a 3-5 year timeframe. A 10x return would necessitate a market cap exceeding $5.7 trillion, ...